医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Berry Global Increases Production to Aid in Coronavirus Protection

2020年02月01日 AM06:42
このエントリーをはてなブックマークに追加


 

EVANSVILLE, Ind.

Today, in response to questions from the investment community on its recent quarterly call, Berry Global Group, Inc. (NYSE: BERY) reports it is prioritizing the production of nonwoven healthcare products in its Nanhai, China and Suzhou, China facilities, which are used to manufacture products that can help protect against airborne particles like the Coronavirus.

Nonwoven materials produced at the facilities are used in face masks, N95 respirators, and protective apparel, all of which have recently been in high demand in the plan to prevent the spread of not only the Coronavirus, but also other communicable diseases.

A look inside the Company’s current Nanhai production efforts can be viewed through media coverage found on its LinkedIn page.

“Our thoughts go out to those affected by the Coronavirus. Our dedicated teams are working around the clock to manufacture as much of these materials as possible to help prevent the spread of the virus,” said Curt Begle, President of Berry’s Health, Hygiene, and Specialties Division.

Berry has advised employees in the affected areas to use extra caution including the use of Company-issued face masks, hand sanitizer, and hand soaps.

About Berry

Berry Global Group, Inc. (NYSE:BERY), headquartered in Evansville, Indiana, is committed to its mission of ‘Always Advancing to Protect What’s Important,’ and proudly partners with its customers to provide them with value-added protective solutions that are increasingly light-weighted and easier to recycle or reuse. The Company is a leading global supplier of a broad range of innovative rigid, flexible, and nonwoven products used every day within consumer and industrial end markets. Berry, a Fortune 500 company, has over 48,000 employees and generated $12.6 billion of pro forma net sales in fiscal year 2019, from operations that span over 290 locations on six continents. For additional information, visit Berry’s website at berryglobal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005586/en/

CONTACT

Berry Media Contact:

Amy Waterman

+1 812.306.2435

amywaterman@berryglobal.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表